<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433888</url>
  </required_header>
  <id_info>
    <org_study_id>JH20563</org_study_id>
    <nct_id>NCT00433888</nct_id>
  </id_info>
  <brief_title>Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients (Phase Ⅲ Study)</brief_title>
  <official_title>Clinical Study of Switching From rHuEPO to R744 and Maintenance Treatment With R744 in Renal Anemia Patients on Hemodialysis (Phase Ⅲ Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and safety of intravenous R744 in renal anemia patients
      on hemodialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients who maintain Hb concentration in the range of ≥ 10.0g/dL and ≤ 12.0g/dL</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Slope of regression line of Hb concentration (g/dL/week)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients who maintain Hb concentration in the range of baseline* ± 1.0g/dL</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients who maintain Hb concentration in the range of ≥ 10.0g/dL and &lt; 13.0g/dL</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory measurements</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs, standard 12-lead ECG</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-R744 antibody titer</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">179</enrollment>
  <condition>Hemodialysis Patients</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R744</intervention_name>
    <description>100μg/4 weeks for 8 weeks,then 25~400μg/4 weeks for 40 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R744</intervention_name>
    <description>150μg/4 weeks for 8 weeks,then 25~400μg/4 weeks for 40 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have been receiving hemodialysis 3 times a week for at least 12 weeks
             before registration

          -  Patients aged ≥ 20 years at the time of obtaining consent Patients who have been
             receiving a rHuEPO preparation at least once a week for at least 8 weeks before
             registration

          -  Patients whose mean value of Hb concentrations determined before the first dialysis of
             each week within 8 weeks prior to the registration has been between ≥ 10.0 g/dL and
             &lt;12.0 g/dL

          -  Patients whose transferrin saturation has been ≥ 20 % or ferritin has been

               -  100ng/mL at any one time point within 8 weeks before registration

        Exclusion Criteria:

          -  Patients with hardly controllable hypertension (patients whose diastolic blood
             pressure has been ≥ 100 mmHg on more than 1/3 of the determining occasions within 12
             weeks before registration)

          -  Patients with congestive cardiac failure (≥ Class III in NYHA cardiac function
             classification)

          -  Female patients who are pregnant, lactating, possibly pregnant or not willing to take
             a contraceptive measure in the period from the day of starting the treatment with the
             study drug to 90 days after the day of the last dose of the study drug

          -  Patients with complication of myocardial infarction, pulmonary infarction or cerebral
             infarction (excluding asymptomatic cerebral infarction)

          -  Patients confirmed to have serious allergy or serious drug allergy (shock,
             anaphylactoid symptom)

          -  Patients hypersensitive to a rHuEPO preparation

          -  Patients with malignant tumor (including hemic malignant tumor), severe infection,
             systemic hemic disease (osteomyelodysplasia syndrome, hemoglobinopathy, etc.),
             hemolytic anemia or apparent hemorrhagic lesion such as digestive tract hemorrhage

          -  Patients who have received an anabolic hormone preparation, testosterone enanthate or
             mepitiostane within 12 weeks before registration

          -  Patients who have received another investigational drug within 12 weeks before
             registration

          -  Patients who have received R744 before registration

          -  Patients whose AST(GOT) value ≥ 100 IU/L or ALT(GPT) value ≥ 100 IU/L before
             registration

          -  Patients who have received erythrocyte transfusion within the last 16 weeks before
             registration

          -  Patients for whom a surgical operation involved with heavy bleeding is planned during
             the study period

          -  In addition, patients who are judged as ineligible to participate in this study by the
             investigator or sub-investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takanori Baba</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Research Department 2</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chubu region</name>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chugoku/Shikoku region</name>
      <address>
        <city>Chugoku/Shikoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido/Tohoku region</name>
      <address>
        <city>Hokkaido/Tohoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto/Koshinetsu region</name>
      <address>
        <city>Kanto/Koshinetsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki/Hokuriku region</name>
      <address>
        <city>Kinki/Hokuriku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyusyu region</name>
      <address>
        <city>Kyusyu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2007</study_first_submitted>
  <study_first_submitted_qc>February 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <last_update_submitted>January 29, 2009</last_update_submitted>
  <last_update_submitted_qc>January 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chugai Pharmaceutical</name_title>
    <organization>Chugai Pharmaceutical</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

